D Vitamini ve İlaç İlaç Etkileşimleri
Özet
D vitamininin kanda 25(OH)D düzeyiyle değerlendirilen eksikliği, birçok kronik ve dermatolojik hastalıkla ilişkili küresel bir sorundur. Son yıllarda çoklu ilaç kullanımıyla birlikte ilaç-ilaç etkileşimleri artmaktadır; bu durum D vitamini için de geçerlidir. Etkileşimler genellikle Faz I (özellikle CYP3A4) ve Faz II metabolizma enzimleri ile P-gp gibi taşıma proteinleri üzerinden farmakokinetik veya nükleer reseptörler (VDR ve PXR) aracılığıyla farmakodinamik mekanizmalarla gerçekleşir. CYP3A4 enzimi hem birçok ilacın biyotransformasyonunda hem de D vitamini metabolizmasında (hidroksilasyon basamaklarında) kritik rol oynar. D vitamini takviyeleri veya aktif formu, bu enzimleri indükleyen veya inhibe eden kortikosteroidler, rifampisin gibi antibakteriyeller, azol grubu antifungaller ve HCQ gibi dermatolojide sık kullanılan ajanlarla etkileşebilir. Örneğin, PXR aktivatörü ilaçlar D vitamini yıkımını artırarak eksikliğe yol açabilirken, HCQ aktif form sentezini inhibe eder. Antihistaminikler ve biyolojik ajanlarla klinik olarak anlamlı etkileşim kanıtı sınırlıdır. Sonuç olarak, özellikle dar terapötik indeksli ilaçlar kullanan hastalarda D vitamini takviyelerinin olası etkileşimleri, hastanın sağlığı ve tedavi başarısı açısından elektronik kayıtlar ve uygulamalar takip edilerek dikkatle değerlendirilmelidir.
Vitamin D deficiency, assessed via 25(OH)D levels, is a global issue linked to chronic and dermatological diseases, while polypharmacy increases drug-drug interactions involving vitamin D. These interactions occur through pharmacokinetic pathways involving Phase I (especially CYP3A4) and Phase II enzymes, and transport proteins like P-gp, or via pharmacodynamic mechanisms involving nuclear receptors such as VDR and PXR. CYP3A4 plays a critical role in both drug biotransformation and vitamin D hydroxylation. Consequently, vitamin D interacts with dermatological drugs that induce or inhibit these pathways, including corticosteroids, antibacterials like rifampin, azole antifungals, and hydroxychloroquine (HCQ). For instance, PXR-activating drugs accelerate vitamin D degradation, while HCQ inhibits its active form synthesis. Evidence regarding significant interactions with antihistamines and biologics remains limited. Therefore, potential vitamin D interactions—especially with narrow therapeutic index drugs—must be carefully monitored using electronic medical records to ensure patient safety and therapeutic efficacy.
Referanslar
Raizada N, Goyal A, Singla R, et al. Changing Trend in Vitamin D Status from 2008 to 2016: An Experience from a Tertiary Care Institute in North India. Indian J Endocrinol Metab. 2020;24(2):150-4.
Yavuz DG. Osteoporoz ve Metabolik Kemik Hastalıkları Tanı ve Tedavi Kılavuzu. (12.09.2018 tarihinde https://www.researchgate.net/publication/303404228_ adresinden ulaşılmıştır).
Gröber U, Reichrath J, Holick MF. Live longer with vitamin D? Nutrients. 2015;7(3):1871-80.
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81.
Wolf G. The discovery of vitamin D: the contribution of Adolf Windaus. J Nutr. 2004;134(6):1299-302.
Gröber U, Schmidt J, Kisters K. Important drug-micronutrient interactions: A selection for clinical practice. Crit Rev Food Sci Nutr. 2020;60(2):257-75.
Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015;54(4):383-92.
Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med. 2012;28(2):173-86.
Ferreira Silva R, Rita Carvalho Garbi Novaes M. Interactions between drugs and drug-nutrient in enteral nutrition: a review based on evidences. Nutr Hosp. 2014;30(3):514-8.
Rekić D, Reynolds KS, Zhao P, et al. Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access. J Pharm Sci. 2017;106(9):2214-8.
Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211-21.
Vadlapatla RK, Patel M, Paturi DK, et al. Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Expert Opin Drug Metab Toxicol. 2014;10(4):561-80.
Girmenia C, Iori AP. An update on the safety and interactions of antifungal drugs in stem cell transplant recipients. Expert Opin Drug Saf. 2017;16(3):329-39.
Brunton LL, Lazo JS, Parker KL. Goodman&Gilman Tedavinin Farmakolojik Temeli 2009:71-93. Nobel Tıp Kitabevleri, İstanbul.
Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol. 1996;24(1):48-57.
Carpenter M, Berry H, Pelletier Al. Clinically Relevant Drug-Drug Interactions in Primary Care. Am Fam Physician. 2019;99(9):558-64.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-41.
Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008;82(10):667-715.
Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533-44.
Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9(4):310-22.
Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34(1-2):83-448.
Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304.
Huang H, Wang H, Sinz M, et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene. 2007;26(2):258-68.
Marechal JD, Yu J, Brown S, et al. In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer. Drug Metab Dispos. 2006;34(4):534-8.
Zhou S, Chan E, Lim LY, et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab. 2004;5(5):415-42.
Boobis A, Watelet JB, Whomsley R, et al. Drug interactions. Drug Metab Rev. 2009;41(3):486-527.
Ghazarian JG, Jefcoate CR, Knutson JC, et al. Mitochondrial cytochrome p450. A component of chick kidney 25-hydrocholecalciferol-1alpha-hydroxylase. J Biol Chem. 1974;249(10):3026-33.
Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21(3):319-29.
Wang P, Qin X, Liu M, Wang X. The burgeoning role of cytochrome P450-mediated vitamin D metabolites against colorectal cancer. Pharmacol Res. 2018;133:9-20.
Heaney RP, Recker RR, Grote J, et al. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab. 2011;96(3):E447-52.
Chun RF, Shieh A, Gottlieb C, et al. Vitamin D Binding Protein and the Biological Activity of Vitamin D. Front Endocrinol (Lausanne). 2019;10:718.
Lindh JD, Björkhem-Bergman L, Eliasson E. Vitamin D and drug-metabolising enzymes. Photochem Photobiol Sci. 2012;11(12):1797-801.
Slominski AT, Kim TK, Hobrath JV, et al. Endogenously produced nonclassical vitamin D hydroxy-metabolites act as "biased" agonists on VDR and inverse agonists on RORα and RORγ. J Steroid Biochem Mol Biol. 2017;173:42-56.
Hashizume T, Xu Y, Mohutsky MA, et al. Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochem Pharmacol. 2008;75(5):1240-50.
Guengerich FP. Cytochrome P450 research and The Journal of Biological Chemistry. J Biol Chem. 2019 Feb 1;294(5):1671-80.
Sassi F, Tamone C, D'Amelio P. Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients. 2018;10(11):1656.
Banerjee A, Ganguly U, Saha S, et al. Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits. Expert Rev Anti Infect Ther. 2021;1:1-14.
Choi MS, Kim YC, Maeng HJ. Therapeutic targets of vitamin D receptor ligands and their pharmacokinetic effects by modulation of transporters and metabolic enzymes. J. Pharm. Investig. 2020;50, 1–16.
Qin X, Wang X. Role of vitamin D receptor in the regulation of CYP3A gene expression. Acta Pharm Sin B. 2019;9(6):1087-1098.
Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005;115(1):177-86.
Holick MF. Stay tuned to PXR: an orphan actor that may not be D-structive only to bone. J Clin Invest. 2005;115(1):32-4.
Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol. 2013;136:54-8.
Roy-Chowdhury J, Locker J, Roy-Chowdhury N. Nuclear receptors orchestrate detoxification pathways. Dev Cell. 2003;4(5):607-8.
Timsit YE, Negishi M. CAR and PXR: the xenobiotic-sensing receptors. Steroids. 2007;72(3):231-46.
Gröber U, Holick MF, Kisters K. Vitamin D3 und Arzneimittel [Vitamin D and drugs]. Med Monatsschr Pharm. 2011;34(10):377-87.
Gröber U, Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol. 2012;4(2):158-66.
Omdahl JL, Bobrovnikova EA, Choe S, et al. Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway. Steroids. 2001;66(3-5):381-9.
Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998;102(5):1016-23.
Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A. 1998;95(21):12208-13.
Falkner KC, Pinaire JA, Xiao GH, et al. Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol Pharmacol. 2001;60(3):611-9.
Staudinger JL, Goodwin B, Jones SA, et al. "The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity". Proceedings of the National Academy of Sciences of the United States of America. 98;(6):3369–74.
Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001;7(5):584-90.
Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276(18):14581-7.
Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23(5):687-702.
Samaras D, Samaras N, Lang PO, et al. Effects of widely used drugs on micronutrients: a story rarely told. Nutrition. 2013;29(4):605-10.
Robien K, Oppeneer SJ, Kelly JA, Hamilton-Reeves JM. Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract. 2013;28(2):194-208.
Cecchin E, De Mattia E, Toffoli G. Nuclear receptors and drug metabolism for the personalization of cancer therapy. Expert Opin Drug Metab Toxicol. 2016;12(3):291-306.
Luo G, Guenthner T, Gan LS, Humphreys WG. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab. 2004;5(6):483-505.
Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest. 1987;80(4):1029-36.
Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 1992;90(5):1871-8.
Thummel KE, Brimer C, Yasuda K, et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol. 2001;60(6):1399-406.
Lindh JD, Andersson ML, Eliasson E, Björkhem-Bergman L. Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. Drug Metab Dispos. 2011;39(5):933-7.
Elmeliegy M, Vourvahis M, Guo C, Wang DD. Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies. Clin Pharmacokinet. 2020;59(6):699-714.
Maestro MA, Molnár F, Carlberg C. Vitamin D and Its Synthetic Analogs. J Med Chem. 2019;62(15):6854-75.
Maestro MA, Molnár F, Mouriño A, Carlberg C. Vitamin D receptor 2016: novel ligands and structural insights. Expert Opin Ther Pat. 2016;26(11):1291-306.
Kupisz-Urbańska M, Płudowski P, Marcinowska-Suchowierska E. Vitamin D Deficiency in Older Patients-Problems of Sarcopenia, Drug Interactions, Management in Deficiency. Nutrients. 2021;13(4):1247.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporos. Int. 2007;18:1319–28.
Prummel MF, Wiersinga WM, Lips P, et al. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab. 1991;72(2):382-6.
Hahn TJ, Halstead LR, Haddad JG Jr. Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med. 1977;90(2):399-404.
Mazahery H, von Hurst PR. Factors affecting 25-Hydroxyvitamin D concentration in response to vitamin D supplementation. Nutrients. 2015;7(7):5111-42.
Searing DA, Zhang Y, Murphy JR, et al. Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol. 2010;125(5):995-1000.
Gentile DM, Tomlinson ES, Maggs JL, et al. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther. 1996;277(1):105-12.
Varis T, Kivistö KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther. 2000;68(5):487-94.
Canalis E. Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab. 1996;81(10):3441-7.
Blahos J, Care AD, Sommerville BA. The effect of betamethasone on duodenal calcium absorption and 1,25-dihydroxy vitamin D3 production in the chick. Horm. Metab. Res. 1983;15:197–200.
Kim MH, Lee GS, Jung EM, et al. The negative effect of dexamethasone on calcium-processing gene expressions is associated with a glucocorticoid-induced calcium-absorbing disorder. Life Sci. 2009;85(3-4):146-52.
Kim MH, Lee GS, Jung EM, et al. Dexamethasone differentially regulates renal and duodenal calcium-processing genes in calbindin-D9k and -D28k knockout mice. Exp Physiol. 2009;94(1):138-51.
Huybers S, Naber TH, Bindels RJ, Hoenderop JG. Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):92-7.
Hahn TJ, Halstead LR, Baran DT. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab. 1981;52(1):111-5.
Brodie MJ, Boobis AR, Dollery CT, et al. Rifampicin and vitamin D metabolism. Clin Pharmacol Ther. 1980;27(6):810-4.
Wang Z, Lin YS, Zheng XE, et al. An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol Pharmacol. 2012;81(4):498-509.
Chocano-Bedoya P, Ronnenberg AG. Vitamin D and tuberculosis. Nutr Rev. 2009;67(5):289-93.
Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008;37(1):113-9.
Kim YC, Kim IB, Noh CK, et al. Effects of 1α,25-dihydroxyvitamin D3, the natural vitamin D receptor ligand, on the pharmacokinetics of cefdinir and cefadroxil, organic anion transporter substrates, in rat. J Pharm Sci. 2014;103(11):3793-805.
Barnes TC, Bucknall RC. Vitamin D deficiency in a patient with systemic lupus erythematosus. Rheumatology 2004;43(3):393-4.
Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med. 2000;6(5):442-7.
Huisman AM, White KP, Algra A, et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol. 2001;28(11):2535-9.
Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology 2008;47(6):920-3.
Princen HM, Meijer P, Wolthers BG, et al. Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis. Biochem J. 1991;275:501-5.
Winegar DA, Salisbury JA, Sundseth SS, Hawke RL. Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells. J Lipid Res. 1996;37(1):179-91.
Souidi M, Parquet M, Férézou J, Lutton C. Modulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase activities by steroids and physiological conditions in hamster. Life Sci. 1999;64(17):1585-93.
Gueguen Y, Ferrari L, Souidi M, et al. Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase. Basic Clin Pharmacol Toxicol. 2007;100(6):392-7.
Grenet O, Bobadilla M, Chibout SD, Steiner S. Evidence for the impairment of the vitamin D activation pathway by cyclosporine A. Biochem Pharmacol. 2000;59(3):267-72.
Reichel H, Grüssinger A, Knehans A, et al. Long-term therapy with cyclosporin A does not influence serum concentrations of vitamin D metabolites in patients with multiple sclerosis. Clin Investig. 1992;70(7):595-9.
de Sévaux RG, Hoitsma AJ, van Hoof HJ, et al. Abnormal vitamin D metabolism and loss of bone mass after renal transplantation. Nephron Clin Pract. 2003;93(1):21-8.
Falkiewicz K, Kamińska D, Nahaczewska W, et al. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation. Transplant Proc. 2006;38(1):119-22.
Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22(5):328-35.
Kailajärvi ME, Salminen EK, Paija OM, et al. Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anticancer Res. 2004;24(2C):1271-4.
Gao Y, Shimizu M, Yamada S, et al. The effects of chemotherapy including cisplatin on vitamin D metabolism. Endocr J. 1993;40(6):737-42.
Fakih MG, Trump DL, Johnson CS, et al. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int J Colorectal Dis. 2009;24(2):219-24.
Bartl R, Bartl C, Gradinger R. Medikamenteninduzierte Osteopathien. Medikamente, Pathogenese, Formen, Diagnostik, Prävention und Therapie [Drug-induced osteopathies. Drugs, pathogenesis, forms, diagnosis, prevention and therapy]. Z Rheumatol. 2010;69(2):135-50.
Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30(2):167-72.
Carpenter M, Berry H, Pelletier AL. Clinically Relevant Drug-Drug Interactions in Primary Care. Am Fam Physician. 2019;99(9):558-64.
Li H, Dou W, Padikkala E, Mani S (November 2013). "Reverse yeast two-hybrid system to identify mammalian nuclear receptor residues that interact with ligands and/or antagonists". Journal of Visualized Experiments (81): e51085. doi:10.3791/51085
Mani S, Dou W, Redinbo MR. "PXR antagonists and implication in drug metabolism". Drug Metabolism Reviews. 2013;45(1):60–72.
Loose DS, Kan PB, Hirst MA, et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983;71(5):1495-9.
Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther. 1992;52(3):231-8.
Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos. 1994;22(6):849-57.
Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem. 2008;15(21):2173-91.
Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet. 2008;47(4):217-30.
Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children. Drug Saf. 2001;24(2):119-47.
Corsico AG, Leonardi S, Licari A, et al. Focus on the cetirizine use in clinical practice: a reappraisal 30 years later. Multidiscip Respir Med. 2019;14:40.
Ghosal A, Gupta S, Ramanathan R, et al. Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009;3(3):162-70.
Hashizume T, Imaoka S, Mise M, et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther. 2002;300(1):298-304.
Rumore MM. Clinical pharmacokinetics of chlorpheniramine. Drug Intell Clin Pharm. 1984;18(9):701-7.
Akamine Y, Yasui-Furukori N, Uno T. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism. Curr Drug Metab. 2019;20(2):124-129.
Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012;16(14):1999-2005.
Xiong Y, Yuan Z, Yang J, et al. CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2016;41(2):117-24.
Richards DA. Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. J Clin Gastroenterol. 1983;5(Suppl 1):81-90.
Saarem K, Pedersen JI. Sex differences in the hydroxylation of cholecalciferol and of 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha-triol in rat liver. Biochem J. 1987;247(1):73-8.
Møller UK, Streym Sv, Jensen LT, et al. Increased plasma concentrations of vitamin D metabolites and vitamin D binding protein in women using hormonal contraceptives: a cross-sectional study. Nutrients. 2013;5(9):3470-80.
Buchanan JR, Santen R, Cauffman S, et al. The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D. Calcif Tissue Int. 1986;39:139–44.
Cheema C, Grant BF, Marcus R. Effects of estrogen on circulating “free” and total 1,25-dihydroxyvitamin D and on the parathyroid-vitamin D axis in postmenopausal women. J Clin Invest. 1989;83:537–42.
Nelson ML, Blum JM, Hollis BW, et al. Supplements of 20 microg/d cholecalciferol optimized serum 25-hydroxyvitamin D concentrations in 80% of premenopausal women in winter. J Nutr. 2009;139(3):540-6.
Angelidis C, Kotsialou Z, Kossyvakis C, et al. Colchicine Pharmacokinetics and Mechanism of Action. Curr Pharm Des. 2018;24(6):659-63.
Konda C, Rao AG. Colchicine in dermatology. Indian J Dermatol Venereol Leprol. 2010;76(2):201-5.
Nast A, Boehncke WH, Mrowietz U, et al. Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10 Suppl 2:S1-95.
Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018;179(5):1205-7.
Syed YY. Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis. Am J Clin Dermatol. 2017;18(1):147-58.
D'Ippolito D, Pisano M. Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. P T. 2018;43(9):532-5.
Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23 Suppl 2:1-70.
Facheris P, Valenti M, Pavia G, et al. Brodalumab: A new way to inhibit IL-17 in psoriasis. Dermatol Ther. 2020;33(3):e13403.
Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68(1):61-76.
Keating GM. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs. 2017;77(4):459-72.
Neema S, Mukherjee S, Vasudevan B, et al. Vitamin D Deficiency After Oral Retinoid Therapy for Ichthyosis. Pediatr Dermatol. 2015;32(4):e151-5.
Fadel L, Rehó B, Volkó J, et al. Agonist binding directs dynamic competition among nuclear receptors for heterodimerization with retinoid X receptor. J Biol Chem. 2020;295(29):10045-61.
Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998;13(3):325-49.
Frankel TL, Seshadri MS, McDowall DB, Cornish CJ. Hypervitaminosis A and calcium-regulating hormones in the rat. J Nutr. 1986;116(4):578–87.
Lim LS, Harnack LJ, Lazovich D, Folsom AR. Vitamin A intake and the risk of hip fracture in postmenopausal women: the Iowa Women's Health Study. Osteoporos Int. 2004;15(7):552-9. Michaëlsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med. 2003;348(4):287-94.
Armağan G. Systemic Retinoids. Turkderm-Turk Arch Dermatol Venereol. 2016; 50(1): 22-5.
Acitretin. Product Monograph. Allergan Inc. 85 Enterprise Blvd., Suite 500 Markham, Ontario L6G 0B5. Date of Preparation: August 10, 2018. 29.05.2021 tarihinde https://pdf.hres.ca/dpd_pm/00040117.PDF tarihinde ulaşılmıştır.)
Isotretinoin Drug Interactions. Treatment Options. (27.06.2021 tarihinde https:// www.drugs.com/drug-interactions/isotretinoin.html adresinden ulaşılmıştır).
El-Hamd MA, El Taieb MA, Ibrahim HM, Aly SS. Vitamin D levels in acne vulgaris patients treated with oral isotretinoin. J. Cosmet. Dermatol. 2019;18(1):16–20.
Miziołek B, Bergler-Czop B, Stańkowska A, Brzezińska-Wcisło L. The safety of isotretinoin treatment in patients with bone fractures. Postepy Dermatol Alergol. 2019;36(1):18–24.
Ertugrul DT, Karadag AS, Tutal E, Akin KO. Therapeutic hotline. Does isotretinoin have effect on vitamin D physiology and bone metabolism in acne patients? Dermatol Ther. 2011;24(2):291–5.
Mülkoğlu C, Karaosmanoğlu N. Effect of Serum 25 Hydroxy Vitamin D Level on Isotretinoin-Induced Musculoskeletal Symptoms: A Cross-Sectional Study. Sci Rep. 2020;10(1):2245.
Fallah H, Rademaker M. Isotretinoin in the management of acne vulgaris: practical prescribing. Int J Dermatol. 2021;60(4):451-60.
Calcipotriene topical Interactions (27.06.2021 tarihinde https://www.drugs.com/drug_interactions.html adresinden ulaşılmıştır).
Mohn ES, Kern HJ, Saltzman E, et al. Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update. Pharmaceutics. 2018;10(1):36.
